Role of dopamine transporter imaging in investigation of parkinsonian syndromes in routine clinical practice

Movement Disorders

Volumn 18, Issue SUPPL. 7, 2003, Pages

  Poewe, Werner ^a,b   Scherfler, Christoph ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b Universitatsklinik fur Neurochirurgie Innsbruck   (Austria)

Author keywords

Differential diagnosis; Dopamine transporter; Parkinsonian disorder; PET; SPECT

Indexed keywords

BIOLOGICAL MARKER; DOPAMINE TRANSPORTER; FLUORINE 18; TRACER; TROPANE DERIVATIVE;

ALZHEIMER DISEASE; ARTICLE; CLINICAL FEATURE; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG INDUCED DISEASE; ESSENTIAL TREMOR; HUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VASCULAR DISEASE;

BRAIN; CORPUS STRIATUM; DIAGNOSIS, DIFFERENTIAL; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; NEURAL PATHWAYS; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; PARKINSONIAN DISORDERS; SENSITIVITY AND SPECIFICITY; SUBSTANTIA NIGRA; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0242288112     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10573     Document Type: Article

References (45)

1. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism: a prospective study. Can J Neurol Sci 1991;18: 275-278.
2. Hughes AJ, Ben Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992;42:1142-1146.
3. Hughes AJ, Ben Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. 1992. Neurology 2001;57:S34-S38.
4. Hughes AJ, Daniel SE, Ben Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125:861-870.
5. Litvan I, MacIntyre A, Goetz CG, et al. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol 1998; 55:969-978.
6. Deuschl G. Differential diagnosis of tremor. J Neural Transm Suppl 1999;56:211-220.
7. Poewe W, Wenning G. The differential diagnosis of Parkinson's disease. Eur J Neurol 2002;9:23-30.
8. 18F]fluoro-dopa and positron emission tomography: error analysis and application to normal subjects. J Cereb Blood Flow Metab 1993;13:43-56.
9. 18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 1993;34:324-330.
10. Uhl GR. Neurotransmitter transporters: a promising new gene family. Trends Neurosci 1992;15:265-268.
11. Asenbaum S, Brucke T, Pirker W, et al. Imaging of dopamine transporters with iodine-[123]-β-CIT and SPECT in Parkinson's disease. J Nucl Med 1997;38:1-6.
12. Innis RB, Seibyl JP, Scanley BE, et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci USA 1993;90:11965-11969.
13. 123I]-β-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996;46:231-237.
14. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301.
15. Benamer HT, Patterson J, Wyper DJ, Hadley DM, Macphee GJ, Grosset DG. Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord 2000; 15:692-698.
16. 18F]dopa PET. J Neurol Neurosurg Psychiatry 1998;64:314-319.
17. 123I]-IBZM-SPECT scanning in levodopa-naive Parkinson's disease. Mov Disord 1998;13:438-445.
18. Marder K, Tang MX, Mejia H, et al. Risk of Parkinson's disease among first-degree relatives: a community-based study. Neurology 1996;47:155-160.
19. Benamer HT, Oertel WH, Patterson J, et al. Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: Part 1. Baseline and 3-month observations. Mov Disord 2003;18:977-984.
20. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003;54:93-101.
21. Chouker M, Tatsch K, Linke R, Pogarell O, Hahn K, Schwarz J. Striatal dopamine transporter binding in early to moderately advanced Parkinson's disease: monitoring of disease progression over 2 years. Nucl Med Commun 2001;22:721-725.
22. Pirker W, Djamshidian S, Asenbaum S, Gerschlager W, Tribl G, Hoffmann M, Brucke T. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal β-CIT SPECT study. Mov Disord 2002;17:45-53.
23. 123I]-β-CIT SPECT. J Neural Transm 2000;107:543-552.
24. 123I]β-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord 2000;15:1158-1167.
25. Schocke MF, Seppi K, Esterhammer R, et al. Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. Neurology 2002;58:575-580.
26. Schulz JB, Skalej M, Wedekind D, et al. Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy. Ann Neurol 1999;45:65-74.
27. Seppi K, Schocke MF, Esterhammer R, et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology 2003;60:922-927.
28. Parkinson Study Group. A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Neurology 2000;55:1540-1547.
29. 123I]-β-CIT and SPECT in essential tremor and Parkinson's disease. J Neural Transm 1998;105:1213-1228.
30. 123I]FP-CIT study group. Mov Disord 2000;15:503-510.
31. Farrer M, Gwinn-Hardy K, Muenter M, et al. A chromosome 4p haplotype segregating with Parkinson's disease and postural tremor. Hum Mol Genet 1999;8:81-85.
32. Critchley M. Arteriosclerotic parkinsonism. Brain 1929;52:23-83.
33. Winikates J, Jankovic J. Clinical correlates of vascular parkinsonism. Arch Neurol 1999;56:98-102.
34. Inzelberg R, Bornstein NM, Reider I, Korczyn AD. Basal ganglia lacunes and parkinsonism. Neuroepidemiology 1994; 13:108 -112.
35. Reider-Groswasser I, Bornstein NM, Korczyn AD. Parkinsonism in patients with lucanar infarcts of the basal ganglia. Eur Neurol 1995;35:46-49.
36. 123I]β-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease. Mov Disord 2002;17:518-523.
37. Huang CC, Yen TC, Weng YH, Lu CS. Normal dopamine transporter binding in dopa responsive dystonia. J Neurol 2002;249:1016-1020.
38. 123I]β-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia. Ann Neurol 1998; 43:792-800.
39. O'Sullivan JD, Costa DC, Gacinovic S, Lees AJ. SPECT imaging of the dopamine transporter in juvenile-onset dystonia. Neurology 2001;56:266-267.
40. 123I]FP-CIT SPECT in the early diagnosis of PD presenting as exercise-induced dystonia. Neurology 2002;59:1974-1976.
41. 123I]β-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 2001;57:2089-2094.
42. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-1661.
43. Ahlskog JE. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology 2003;60:381-389.
44. Wooten GF. Agonists vs. levodopa in PD: the thrilla of whitha. Neurology 2003;60:360-362.
45. 123I]β-CIT SPECT. Mov Disord 2001;